Kieron Dunleavy

9.9k total citations · 1 hit paper
149 papers, 5.6k citations indexed

About

Kieron Dunleavy is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Kieron Dunleavy has authored 149 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 120 papers in Pathology and Forensic Medicine, 71 papers in Oncology and 52 papers in Genetics. Recurrent topics in Kieron Dunleavy's work include Lymphoma Diagnosis and Treatment (120 papers), Chronic Lymphocytic Leukemia Research (51 papers) and CNS Lymphoma Diagnosis and Treatment (39 papers). Kieron Dunleavy is often cited by papers focused on Lymphoma Diagnosis and Treatment (120 papers), Chronic Lymphocytic Leukemia Research (51 papers) and CNS Lymphoma Diagnosis and Treatment (39 papers). Kieron Dunleavy collaborates with scholars based in United States, Germany and Spain. Kieron Dunleavy's co-authors include Wyndham H. Wilson, Elaine S. Jaffe, Stefania Pittaluga, Seth M. Steinberg, Louis M. Staudt, Nicole Grant, Richard F. Little, John E. Janik, Margaret Shovlin and Clíona Grant and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Kieron Dunleavy

140 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

2010 663 citations Wyndham H. Wilson, Owen A. O’Connor et al. The Lancet Oncology profile →

Peers

Kieron Dunleavy

PFM

ONCOL

GENET

NEURO

Michelle A. Fanale United States

Jan Walewski Poland

Mats Jerkeman Sweden

Lisa M. Rimsza United States

Ann S. LaCasce United States

Sonali M. Smith United States

Carol S. Portlock United States

Peter Borchmann Germany

John Kuruvilla Canada

Alain Delmer France

Michelle A. Fanale United States

Kieron Dunleavy

4.1k ×1.1

PFM

3.9k ×1.4

ONCOL

1.2k ×0.7

GENET

1.2k ×0.9

NEURO

843 ×0.8

Citations per year, relative to Kieron Dunleavy Kieron Dunleavy (= 1×) peers Michelle A. Fanale

Countries citing papers authored by Kieron Dunleavy

Since Specialization

Citations

This map shows the geographic impact of Kieron Dunleavy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kieron Dunleavy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kieron Dunleavy more than expected).

Fields of papers citing papers by Kieron Dunleavy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kieron Dunleavy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kieron Dunleavy. The network helps show where Kieron Dunleavy may publish in the future.

Co-authorship network of co-authors of Kieron Dunleavy

This figure shows the co-authorship network connecting the top 25 collaborators of Kieron Dunleavy. A scholar is included among the top collaborators of Kieron Dunleavy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kieron Dunleavy. Kieron Dunleavy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Alig, Stefan, Bjoern Chapuy, Daisuke Ennishi, Kieron Dunleavy, & Daniel J. Hodson. (2024). Evolving molecular classification of aggressive B‐cell lymphoma. Histopathology. 86(1). 94–105.

Campo, Elı́as, Daan Dierickx, Stefan Dirnhofer, et al.. (2024). Lymphoma Classifications, How to Develop a Future Unified Taxonomy. Journal of Clinical Oncology. 42(27). 3177–3182. 7 indexed citations

Kamboj, Mini, Kari Bohlke, Kieron Dunleavy, et al.. (2024). Vaccination of Adults With Cancer: ASCO Guideline. Journal of Clinical Oncology. 42(14). 1699–1721. 36 indexed citations

Cook, Michael, et al.. (2023). Improved survival for dose-intensive chemotherapy in primary mediastinal B-cell lymphoma: a systematic review and meta-analysis of 4,068 patients. Haematologica. 109(3). 846–856. 7 indexed citations

Lue, Jennifer Kimberly, Don A. Stevens, Emmeline Ayers, et al.. (2023). PHASE 1 TRIAL OF KT‐413, A DEGRADER OF IRAK4 AND IMID SUBSTRATES, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN’S LYMPHOMAS. Hematological Oncology. 41(S2). 808–809.

Ali, Alaa M., André Goy, & Kieron Dunleavy. (2022). CAR T-cell therapy in highly aggressive B-cell lymphoma: emerging biological and clinical insights. Blood. 140(13). 1461–1469. 13 indexed citations

Cook, Michael, Kepher H. Makambi, Yutong Luo, et al.. (2022). Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Advances. 7(1). 32–39. 61 indexed citations

Ahlman, Mark A., Christopher Melani, Stefania Pittaluga, et al.. (2019). Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR. Blood. 134(Supplement_1). 4080–4080.

Saba, Nakhle S., Delong Liu, Sarah E. M. Herman, et al.. (2016). Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma. Blood. 128(1). 82–92. 111 indexed citations

10.

Fowler, Nathan, Chan Y. Cheah, Randy D. Gascoyne, et al.. (2016). Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica. 101(5). 531–540. 68 indexed citations

11.

Lai, Catherine & Kieron Dunleavy. (2013). NK/T-cell lymphomas in children. Best Practice & Research Clinical Haematology. 26(1). 33–41. 5 indexed citations

12.

Weniger, Marc A., Edgar Gil Rizzatti, Patricia Pérez‐Galán, et al.. (2011). Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma. Clinical Cancer Research. 17(15). 5101–5112. 82 indexed citations

13.

Dunleavy, Kieron, Richard F. Little, Stefania Pittaluga, et al.. (2010). The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 115(15). 3017–3024. 123 indexed citations

14.

Landgren, Ola, James J. Goedert, Charles S. Rabkin, et al.. (2010). Circulating Serum Free Light Chains As Predictive Markers of AIDS-Related Lymphoma. Journal of Clinical Oncology. 28(5). 773–779. 80 indexed citations

15.

Wilson, Wyndham H., Owen A. O’Connor, Myron S. Czuczman, et al.. (2010). Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. The Lancet Oncology. 11(12). 1149–1159. 663 indexed citations breakdown →

16.

Grant, Clíona, Wyndham H. Wilson, & Kieron Dunleavy. (2010). Neutropenia associated with rituximab therapy. Current Opinion in Hematology. 18(1). 49–54. 27 indexed citations

17.

Dunleavy, Kieron, Stefania Pittaluga, Myron S. Czuczman, et al.. (2009). Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 113(24). 6069–6076. 371 indexed citations

18.

Wilson, Wyndham H., Kieron Dunleavy, Stefania Pittaluga, et al.. (2008). Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers. Journal of Clinical Oncology. 26(16). 2717–2724. 217 indexed citations

19.

Dunleavy, Kieron. (2006). Rituximab, chemotherapy, and HIV-associated lymphoma. Blood. 107. 3015. 1 indexed citations

20.

Neelapu, Sattva S., Larry W. Kwak, Carol B. Kobrin, et al.. (2005). Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nature Medicine. 11(9). 986–991. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact